LivaNova (NASDAQ:LIVN) Announces Earnings Results

LivaNova (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.20, Briefing.com reports. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $357.80 million during the quarter, compared to analysts’ expectations of $342.32 million. During the same quarter in the previous year, the business earned $0.90 EPS. LivaNova’s revenue was up 12.5% compared to the same quarter last year. LivaNova updated its FY 2025 guidance to 3.800-3.90 EPS.

LivaNova Price Performance

Shares of NASDAQ LIVN traded down $2.47 during mid-day trading on Wednesday, reaching $51.47. The company had a trading volume of 713,522 shares, compared to its average volume of 663,931. The stock has a market cap of $2.81 billion, a PE ratio of -13.25 and a beta of 0.95. The company has a 50-day moving average price of $54.36 and a two-hundred day moving average price of $48.11. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. LivaNova has a 1-year low of $32.48 and a 1-year high of $58.91.

Hedge Funds Weigh In On LivaNova

A number of institutional investors have recently made changes to their positions in LIVN. State of Wyoming bought a new position in LivaNova during the second quarter valued at about $31,000. EverSource Wealth Advisors LLC lifted its holdings in shares of LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares in the last quarter. Strs Ohio bought a new position in shares of LivaNova during the 1st quarter worth approximately $130,000. Headlands Technologies LLC increased its stake in LivaNova by 270.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,456 shares of the company’s stock valued at $156,000 after buying an additional 2,524 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new stake in shares of LivaNova in the second quarter valued at about $218,000. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on LIVN. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Barclays boosted their price objective on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. The Goldman Sachs Group set a $55.00 price objective on LivaNova and gave the stock a “neutral” rating in a research report on Wednesday, October 1st. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.